Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of ...

Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approvedSabirnetug is the first monoclonal antibody candidate to enter the clinic developed to selectively target toxic

Related Keywords

Switzerland ,New Hampshire ,United States ,Stefan Egli ,James Doherty ,Acumen Pharmaceuticals ,Exchange Commission ,Capsules Health Ingredients ,Lonza Group Ltd ,Acumen Pharmaceuticals Inc ,Global Head ,Mammalian Biologics ,Chief Development Officer ,Small Molecules ,Looking Statements ,Private Securities Litigation Reform Act ,Annual Report ,Contact Details ,Acumen Contact Details ,Region ,